CompletedPhase 3

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea

United States377 participantsStarted 2002-02

Plain-language summary

This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes. Patients will be randomized into one of two AC2993 treatment arms or to placebo treatment and will continue with their required existing diabetes medication (sulfonylurea) throughout the study.

Who can participate

Age range16 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subjects with Type 2 diabetes mellitus * Treated with a sulfonylurea at defined doses for at least 3 months prior to screening * BMI= 27-45 kg/m2 * HbA1c value between 7.5% and 11% Exclusion Criteria: * Treated with oral anti-diabetic medications other than a sulfonylurea within 3 months of screening * Patients treated previously with AC2993 * Patients presently treated with insulin

What they're measuring

Change in HbA1c from Baseline to Week 30

Timeframe: Baseline (Day 1) to Week 30

Trial details

NCT IDNCT00039026

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2003-08

View on ClinicalTrials.gov More Diabetes Mellitus, Non-Insulin-Dependent trials